Impact of gene polymorphisms on the systemic toxicity to paclitaxel/carboplatin chemotherapy for treatment of gynecologic cancers.

Clarissa Lourenço de CastroLuiz Carlos da Costa JuniorLetícia Vieira LourençoKarine Souza SebaTaiana Sousa Lopes da SilvaRosane Vianna-Jorge

Published in: Archives of gynecology and obstetrics (2019)

The present study suggests that CYP2C8*3 is a potential predictor of hematological toxicities related to paclitaxel/carboplatin treatment. Since hematological toxicities, especially neutropenia, may lead to dose delay or treatment interruption, such prognostic evaluation may contribute to clinical management of selected patients with paclitaxel-based chemotherapy.

Keyphrases

randomized controlled trial
clinical trial
oxidative stress
chemotherapy induced
risk assessment
phase ii study
combination therapy
young adults
endometrial cancer